Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of “Moderate Buy” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $16.71.

ELAN has been the subject of a number of research analyst reports. TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. Barclays lifted their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Morgan Stanley raised their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Finally, The Goldman Sachs Group lifted their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th.

Elanco Animal Health Price Performance

ELAN opened at $13.53 on Friday. The firm has a market capitalization of $6.69 billion, a PE ratio of -5.41, a price-to-earnings-growth ratio of 1.42 and a beta of 1.34. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. The business’s 50-day moving average is $15.08 and its two-hundred day moving average is $13.92. Elanco Animal Health has a 1 year low of $7.88 and a 1 year high of $16.88.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the company earned $0.19 EPS. The company’s revenue was up 5.1% on a year-over-year basis. Research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director R David Hoover acquired 20,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average price of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently made changes to their positions in the company. Hunter Associates Investment Management LLC grew its position in Elanco Animal Health by 5.1% during the first quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock valued at $269,000 after buying an additional 800 shares during the period. Treasurer of the State of North Carolina grew its position in shares of Elanco Animal Health by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 221,460 shares of the company’s stock valued at $2,489,000 after acquiring an additional 1,107 shares during the period. Bfsg LLC grew its position in shares of Elanco Animal Health by 8.2% during the 1st quarter. Bfsg LLC now owns 14,885 shares of the company’s stock valued at $242,000 after acquiring an additional 1,125 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Elanco Animal Health by 10.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock valued at $181,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Commerce Bank raised its holdings in Elanco Animal Health by 3.8% in the 4th quarter. Commerce Bank now owns 33,665 shares of the company’s stock worth $502,000 after purchasing an additional 1,223 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.